“In addition, we expect journal account AUM to maintain mid-single-digit growth.”

In context

“iven the exceptional private equity returns in 2021 as well as 2021 benefiting from higher mortgage pay-downs and excess mortality gains, we believe were likely due to COVID. For MetLife Holdings, we are expecting adjusted PFOs to decline between 6% to 8% annually higher than our prior guidance of 5% to 7%. We are lowering the life interest adjusted benefit ratio to 45% to 50% in 2022 from the prior 50% to 55% in 2021 to reflect the impact of lowering the policyholder dividend levels. Finally, we are maintaining the adjusted earnings guidance of $1 billion to $1.2 billion in 2022. Now let’s look at the near-term guidance for our businesses outside the U.S. on Page 14. For Asia, we expect the recent sales momentum to continue and generate mid to high single-digit growth over the near-term. In addition, we expect journal account AUM to maintain mid-single-digit growth. We are expecting mid-single-digit adjusted earnings growth when excluding the excess VII over plan of approximately $800 million post tax in 2021. In Latin America, we expect adjusted PFOs to grow by high single digits over the near-term. Relative to its 2021 reported adjusted earnings, we expect Latin America adjusted earnings to double in 2022, excluding COVID impacts, and then grow by high single to low double digits in 2023 and 2024. Finally, for EMEA, we expect sales to grow mid to high single-digits over the near-term. We expect adjusted earnings and PFOs to decline in 2022 due to the impact from the stronger U.S. dollar and divestitures in the region. For 2023 and 2024, we expect to me adjusted earnings and PFOs to grow to mid to high single-digits on a constant currency basis. Let”